In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-up, we’re looking at a rapidly growing population of patients who will need monitoring for years—sometimes decades.

Featuring insights from Gordon Cummings, Global Growth Lead, this episode highlights why long-term follow-up is essential, how sponsors can reduce burden on patients and sites, and the exciting role of data technologies in making these studies more efficient.